صلب الشرايين المرتبط بالعمر: آليات شيخوخة الأوعية الدموية، والشيخوخة الخلوية، والتخفيف متعدد الوسائط

مراجعة سردية

ملخص

تصلب الشرايين أمراض القلب والأوعية الدموية يرفع بشكل حاد مع تقدم العمر، لكن العمر الزمني ليس تعرضاً مسبباً واحداً. تبحث هذه المراجعة السردية في كيفية تراكم أبروليپوبروتين مُحتَوٍ على البورون بروتين دهني التعرض يتفاعل مع إعادة الهيكلة الوعائية المرتبطة بالعمر،, الشيخوخة الخلوية, ، والخلل الوظيفي الميتوكوندري، واختلال مراقبة جودة الميتوكوندريا، وتكون الدم النسلي. والدلة مفصولة بوضوح إلى مستويات بشرية عشوائية، وبشرية رصديّة/نسيجية/جينية، وما قبل السريرية. تدعم البيانات البشرية إعادة تشكيل المصفوفة خارج الخلية المرتبطة بالعمر، وتصلب الشرايين، والأنماط الظاهرية المرتبطة بالشيخوخة، وتكون الدم النسلي كمساهمين في المخاطر الوعائية، في حين أن العديد من آليات الميتوكوندريا والعلاج الشيخوخي تظل في الغالب مرحلة ما قبل السريرية. ويظل التخفيف السريري متعدد الوسائط: تدعم الأدلة العشوائية خافض للدهون في الوقاية الثانوية, السيطرة على ضغط الدم لدى كبار السن، واختيار استراتيجيات غذائية ومضادة للالتهابات في فئات سكانية محددة، في حين أن الأدلة المخصصة لـ ستاتين التشغيل في الوقاية الأولية يظل محدوداً بعد سن الخامسة والسبعين. الأدوية الحالة للخلايا الهرمة, البلعمة الذرية للميتوكوندريا لم تُظهر المُحسِّنات وغيرها من الاستراتيجيات المُطيلَة للعمر أيَّ فائدة سريرية في النتائج المُتعلقة بتصلب الشرايين لدى البشر. الشيخوخة الوعائية يضيف آليات إلى، بدلاً من أن يحل محل، الآليات التراكمية بوساطة البروتينات الدهنية تكون العصيد الشرياني, وتتبدل قوة الأدلة بشكل كبير عبر المسارات المقترحة.

كلمات مفتاحية تصلب الشرايين; شيخوخة الأوعية الدموية؛ الهرم الخلوي؛ تكون الدم النسلي؛ الخلل الوظيفي الميتوكوندري؛ كبار السن؛ الوقاية القلبية الوعائية.

نهج مراجعة وتقييم الأدلة

هذا سرد وليس مراجعة منهجية. تم اختيار المصادر لتمثل الأدبيات الآلية والسريرية الرئيسية المتعلقة بتصلب الشرايين المرتبط بالعمر، وتم التحقق من الادعاءات الكمية مقابل المنشورات الأولية عندما تكون متاحة بدلاً من قبولها من الاستشهادات الثانوية أو المراجعة.

تُستمد الادعاءات من ثلاث فئات، يُحافظ على استقلالها طوال الوقت: (أولاً) أدلة التجارب العشوائية في البشر؛ (ثانياً) الأدلة الرصدية والنسيجية والوراثية-الوبائية في البشر؛ و(ثالثاً) الأدلة الميكانيكية وما قبل السريرية في نماذج الخلايا والحيوانات. تُصنَّف نتائج الفئة (ثالثاً) على أنها ما قبل سريرية أينما ظهرت وليست قابلة للتطبيق السريري. ولا تُفسَّر الارتباطات الرصدية البشرية على أنها تُؤسِّس لوساطة سببية ما لم تكن مدعومة بأدلة تدخلية أو جراثيمية (وراثية) أو تجريبية متقاربة. تشير تسميات فئات الأدلة داخل الجداول إلى المصادر المُستشهد بها في هذا الصف، وليس إلى المجال عموماً.

تضمن هذه المراجعة السردية عدم وجود تسجيل أصلي للمشاركين البشر أو الحيوانات، وعدم توليد أي بيانات محددة الهوية على مستوى المشاركين.

1. الحركيات الوبائية عبء الأمراض في متأخرات العمر

تصلب الشرايين هو مرض التهابي تقدمي في جدار الشريان يبدأ مبكراً في الحياة، وترتفع نسبة حدوث الأحداث العصيدية السريرية بشكل حاد مع تقدم العمر [2التغيرات المرتبطة بالعمر في جدار الأوعية الدموية — ومنها إعادة تشكيل المصفوفة، والشيخوخة، وخلل الميتوكوندريا ضعف التحكم في جودتها، وتولد الدم النسلي — تورطت في تكوين تصلب الشرايين، وفي النماذج التجريبية والدراسات القلاصية البشرية، في السمات المرتبطة بـ لوحة الهشاشة. هذا لا يثبت أن المعدل الطولي لتراكم اللويحات البشرية نفسها يزداد بشكل غير خطي مع العمر الزمني؛ لم يتم إثبات هذه القضية، ولا تزال العتبات ذات المغزى السريري لتطور اللويحات التاجية غير حاسمة.

العمر هو أحد أقوى العوامل المسببة لخطر الإصابة بأمراض القلب والأوعية الدموية تصلب الشرايين (ASCVD) المتوقع المطلق في نماذج المخاطر المعاصرة32]. هذه عبارة عن بيان حول الوزن ضمن نماذج المخاطر، وليست إثباتاً على أن العمر يتفوق على التعرض التراكمي للدهون كعنصر مسبب رئيسي؛ فالاثنين غير قابلين للمقارنة، لأن العمر يدمج جزئياً وقت التعرض. الخطوط الدهنية وانար تثخن الغلاف الداخلي تتطور في سن المراهقة وبداية البلوغ، بينما تكون سريرياً انسدادية، وغير مستقرة، ومتكلسة آفات تصبح منتشرة بشكل متزايد بعد العقد السادس2].

قد تصبح مساهمة الآليات الإضافية المرتبطة بالعمر أكثر صلة عبر مراحل الحياة2]. في البالغين الشباب ومنوسطي العمر، تتطلب تصلب الشرايين التعرض التراكمي إلى البروتينات الدهنية التي تحتوي على بروتين شحمي ب6] ويقودها بشكل مهم ذلك التعرض جنباً إلى جنب مع تدخين, ضغط الدم, مرض السكري, ، وغيرها من العوامل المسببة، على خلفية إصلاح وعائي سليم نسبياً [2]. لا يمكن ترتيب المساهمة النسبية لهذه التعرضات من البيانات المجمعة هنا. لدى كبار السن، تستمر العملية المدفوعة بالدهون وتتراكب على شيخوخة الأوعية الدموية الذاتية للخلايا، والطفرات الجسدية المكونة للدم، واضعاف مراقبة جودة الالتهام الذاتي، وتدهور المصفوفة خارج الخلية [2الفرق هو فرق في الآلية المضافة، وليس في الآلية المستبدلة.

الفئات العمرية المستخدمة في هذا الاستعراض - 20-39، 40-59، 60-79، و80 عاماً فأكثر - هي إطار تنظيمي توضيحي وليست عتبات بيولوجية مستمدة تجريبياً. لم يتم ربط أي نقطة انعطاف في الآليات التي تمت مناقشتها بنعمر زمني محدد لدى البشر؛ بل إن هذه الفئات هي وسيلة للعرض وتتطابق بشكل عام مع شرائح الترصد الشائعة.

1.0 ما الذي تعنيه “المسارعة” في هذه المراجعة

ونظراً لأن مصطلح تصلب الشرايين المتسارع يُستخدم بشكل غير متسق، فإنه يُعرّف إجرائياً هنا على أنه عبء تصلب الشرايين، أو الخلل الوظيفي الأوعية الدموية، أو بصمة الشيخوخة البيولوجية، أو أمراض القلب والأوعية الدموية تصلب الشرايين السريري الذي يحدث في وقت مبكر، أو بدرجة أكبر، أو يتقدم بشكل أسرع مما هو متوقع بالنسبة للعمر الزمني والتعرض لعوامل الخطر التقليدية المقاسة.

هذه أنماط ظاهرية تشغيلية بديلة للشيخوخة الوعائية وتصلب الشرايين المتسارعة وليست مظاهر لبنية واحدة مثبتة. وهي غير قابلة للتبادل، ويتم قياسها بأدوات مختلفة، وقد يستوفي الشخص معياراً واحداً دون الآخر. إن ضعف الوظيفة الوعائية وبصمات الشيخوخة البيولوجية ليست مقاييس لعبء تصلب الشرايين؛ وقد جُمعت هنا فقط لأن نفس المصطلحات تُطبق عليها في الأدبيات. طوال هذه المراجعة، تشير الشيخوخة الوعائية إلى التغيرات الهيكلية والوظائفية المرتبطة بالعمر في شريان الجدار بصرف النظر عن اللويحة؛ ويشير الشيخوخة تصلب الشرايين إلى المجموعة الفرعية من هذا التغيير المتعلق بتكوين اللويحة أو تركيبها؛ ويُخصص تصلب الشرايين المتسارع للأنماط الظاهرية التشغيلية المذكورة أعلاه.

الجدول 1. التصنيفات التشغيلية البديلة المجمعة تحت “تصلب الشرايين المتسارع”.” هذه بنايات متميزة ذات قواعد قياس متميزة؛ والجدول ليس نظام تدريج، وليست هناك عتبة مصادق عليها سريرياً لاتخاذ القرار الفردي.

Phenotype	Typical measurement basis	What an abnormal result establishes	Principal limitation
Excess anatomic burden for age	Coronary artery calcium score, carotid plaque area or number, CCTA حجم اللويحة	Burden exceeds an age- and sex-referenced distribution; some reference sets are additionally stratified by race or ethnicity	Percentile position is not a progression rate; reference distributions are cohort-specific
Accelerated structural progression	Serial IMT, serial CAC, serial CCTA plaque volume, primarily in research settings	Change over time exceeds that observed in an appropriate reference population or a prespecified research threshold	Requires two standardized measurements; change may approach or fall below the resolution of an individual examination
Vascular functional impairment	Pulse wave velocity, flow-mediated dilation, central pressure augmentation	Arterial stiffening or اختلال وظيفة بطانة الأوعية الدموية exceeding an age reference	Functional measures correlate imperfectly with عبء اللويحات
Biological-aging signature	Epigenetic and proteomic age estimators, telomere length, senescence markers	A biological-aging estimator indicates greater age-associated molecular change than expected for chronological age	Research measures; no validated treatment threshold
Premature clinical ASCVD	Event occurring at an unusually young age according to the study or guideline definition used	Clinical disease earlier than population expectation	An event is a discrete endpoint, not a rate

1.1 Prevalence and incidence — with attention to case definition

Prevalence figures for “cardiovascular disease” in older adults are routinely quoted without the definitional caveat that drives them. In American Heart Association surveillance, the composite CVD category includes ارتفاع ضغط الدم. Using NHANES 2015-2018 data as reported in AHA surveillance, CVD prevalence at ages 60-79 years is 77.5% in males and 75.4% in females, rising to 89.4% and 90.8%, respectively, at age 80 years and older [3]. Narrowing the case definition to مرض الشريان التاجي in the same data yields substantially lower figures: 22.0% of males and 13.4% of females at ages 60-79, and 33.9% and 21.6% at age 80 and older [3]. Because this review concerns atherosclerosis rather than blood pressure, the coronary heart disease figures are more directly relevant; widely circulated estimates near 86-90% should be understood as hypertension-inclusive.

The 2015-2018 NHANES cycle is used because it provides the sex- and age-stratified comparison required here. More recent surveillance is available in the 2026 Statistical Update [4]. Age-specific rates of first cardiovascular events likewise rise markedly across later decades of life [4]. Absolute rates are sex-, calendar-period-, ascertainment-, and case-definition-specific, so no single set of point estimates is quoted here.

1.2 The “lipid paradox” in the very old

An epidemiological nuance in octogenarians and nonagenarians is attenuation, and sometimes inversion, of traditional risk-factor associations — the so-called lipid paradox, described in early form three decades ago [5] and still debated [34]. Three explanations dominate and are not mutually exclusive: السببية العكسية و ربط مربك by illness, because frailty, occult malignancy, chronic infection, فشل القلب, and protein-energy wasting can lower كوليسترول [5]; survivorship selection, because those most susceptible to LDL-driven atherogenesis may disproportionately have experienced events or died before the ninth decade; and competing risk, because a rising hazard of non-atherosclerotic death changes observed cause-specific and cumulative-incidence relationships.

Attenuation of an observational association in the very old is not evidence against البروتين الدهني منخفض الكثافة causality. Genetic evidence supports LDL causality across the life course, and randomized statin evidence demonstrates reduction in major vascular events among older adults, particularly those with established vascular disease [6,7]. Absolute ASCVD burden remains highest in older adults [3,4], reflecting age-associated vascular remodeling superimposed on decades of lipoprotein exposure [2].

1.3 Risk models and biological thresholds

Contemporary prediction frameworks incorporate age as a continuous covariate and do not specify a discrete biological age threshold. This is a property of model structure rather than a finding about vascular biology: the absence of a threshold term in a prediction equation is not evidence that no biological inflection exists, and a strong age coefficient is not evidence that one does.

Table 2. Age-stratified disease burden and illustrative mechanisms. Prevalence values are drawn from AHA surveillance [3] and are shown only for the strata that source reports directly; an em dash indicates that no directly reported age- and sex-stratified value was available. Age assignments are illustrative and do not indicate biological onset, exclusivity, or a validated staging system.

Age cohort (years)	CVD prevalence, hypertension-inclusive [3]	CHD prevalence [3]	Mechanisms highlighted in this age band (Sec.)	Common ASCVD manifestations
20-39	—	—	Endothelial dysfunction, diffuse intimal thickening, early lipid retention (2.1)	Silent fatty streaks, early lipid-rich lesions
40-59	—	—	The above, plus cumulative أبو ب-١٠٠ exposure, VSMC migration and phenotype switching (1, 2.2)	Stable ذبحة صدرية, acute coronary syndromes
60-79	77.5% M / 75.4% F	22.0% M / 13.4% F	The above, plus vascular senescence, stiffening, mitochondrial ROS, تکلس (2.1-2.4)	Myocardial infarction, سكتة دماغية إِشْكِيميّة, claudication
80+	89.4% M / 90.8% F	33.9% M / 21.6% F	The above, plus rising CHIP prevalence, cumulative إلاستين and matrix remodeling, and age-associated impairment of vascular repair (2.5-2.6)	Complex multivessel CAD; ischemic سكتة دماغية; peripheral or multiterritory atherosclerotic disease

2. Intrinsic and extrinsic mechanisms of vascular aging

2.1 Extracellular matrix remodeling, glycation, and hemodynamic shear stress

Aging alters the mechanical properties of central elastic arteries, establishing a biophysical feedback loop proposed to promote atherogenesis [8]. Chronic pulsatile stress triggers elastolysis, elastase up-regulation, and fraying of elastin fibrils, with compensatory collagen deposition and cross-linking [8]. Cumulative glycemic exposure contributes to formation and accumulation of advanced glycation end-products (AGEs) on long-lived structural بروتينات; these modifications are subject to slow turnover rather than being strictly irreversible [8]. AGE cross-linking of collagen impairs compliance [8], while AGE-RAGE engagement activates endothelial NF-kB signaling and amplifies inflammatory and adhesion-molecule expression [61]. AGE accumulation is one contributor among several to age-related arterial stiffening.

The hemodynamic consequence is stiffening, manifest as rising carotid-femoral pulse wave velocity and central systolic pressure, with diastolic pressure typically falling at the population level after the sixth decade and pulse pressure widening [8].

Regions exposed to low or oscillatory endothelial shear stress (ESS) — the tangential frictional force of flowing blood, expressed in dyn/cm2 — are preferentially atheroprone [9]. Reported physiological and low-ESS ranges vary by vessel, methodology, species, and temporal averaging and should be treated as experimental reference ranges rather than universal thresholds. Values of roughly 15-70 dyn/cm2 have been reported for relatively straight segments under pulsatile unidirectional flow, whereas disturbed-flow regions at bifurcations, curvatures, and outer branch walls may show time-averaged magnitudes below approximately 10-12 dyn/cm2 or oscillatory ESS with a near-zero time average [9]. Low ESS down-regulates eNOS, up-regulates VCAM-1 و ICAM-1, and facilitates lipoprotein retention and monocyte transendothelial migration [9].

An aging-specific qualification is important. Aging dilates and stiffens arteries [8], and low-ESS regions are atheroprone [9], but the composite claim that aging enlarges low-ESS territory has not been clearly demonstrated in aging-specific human hemodynamic studies. Age-related geometric and mechanical change may expand low-ESS zones; testing this directly in age-stratified تصوير الأوعية المرجلة بالشرايين التاجية بالأشعة المقطعية cohorts with computational fluid dynamics would be informative.

2.2 Local renin-angiotensin signaling in the aged arterial wall

Two facts are commonly conflated in secondary literature and are separated here. First, arterial-wall angiotensin II (Ang-II) is locally regulated and can differ substantially from circulating levels [10]. Tissue and plasma measurements are not methodologically equivalent, so this should be understood as compartmental separation rather than as a simple concentration ratio. That separation is present across adult life and is not itself an age-related increase.

Second, multiple components of the local renin-angiotensin system — including angiotensinogen, ACE and chymase activity, Ang-II abundance, and AT1-receptor signaling — have been reported to increase in aged arterial tissue across animal models and human tissue studies, whereas plasma renin activity and circulating Ang-II tend to fall with age [10,11]. The intramural age-associated increase should not be conflated with the tissue-to-plasma compartmental difference.

Local Ang-II acts as a mitogen and pressor agent, driving vascular smooth-muscle cell (VSMC) hypertrophy, synthetic phenotype switching, migration, and matrix metalloproteinase secretion, particularly MMP-2 [10,11].

In 16-year longitudinal follow-up of the Malmö Diet and Cancer cohort, mean common carotid intima-media thickness progressed at 0.011 mm/year in men and 0.010 mm/year in women, with faster progression at the bifurcation (0.036 and 0.030 mm/year, respectively) [12]. Approximately 0.01 mm/year, or 0.1 mm per decade for the common carotid, is therefore a reasonable summary of these longitudinal data. Cross-sectional age-reference studies report larger between-age differences [8,13], but cross-sectional and longitudinal quantities should not be arithmetically converted into one another. Carotid IMT also incorporates non-atherosclerotic medial hypertrophy and adaptive wall thickening and is therefore a structural readout rather than a direct measure of plaque accumulation.

2.3 Cellular senescence and the senescence-associated secretory phenotype

DNA damage, telomere attrition, and chronic oxidative stress up-regulate the cyclin-dependent kinase inhibitors p16INK4a and p21CIP1/WAF1, producing durable replicative arrest in vascular endothelial cells and VSMCs [1,14]. In human atherectomy and endarterectomy specimens, cells displaying senescence-associated beta-galactosidase positivity together with shortened telomeres concentrate at atherosclerotic sites and are largely absent from adjacent non-diseased tissue [14]. Neither marker is individually specific for senescence, so these findings identify a senescence-associated phenotype rather than definitively identifying الخلايا الهرمة.

Senescent cells develop a pro-inflammatory senescence-associated secretory phenotype (SASP), including secretion of IL-6, IL-1beta, TNF-alpha, MCP-1/CCL2, and matrix-degrading enzymes such as MMP-2 and MMP-9 [1,15]. Human observational data show senescence-associated markers co-localizing with advanced lesion regions and intraplaque calcification [14-16]. Animal studies show that genetic or pharmacological senescent-cell targeting can reduce SASP-related signaling, matrix degradation, calcification, or vascular dysfunction [15,45]. Fibrous-cap thinning and impaired re-endothelialization are mechanistically coherent consequences, but causal sequences are not established in humans [15].

Senescence in plaque is not uniformly deleterious. VSMCs are essential for fibrous-cap matrix and stability, whereas VSMC senescence impairs proliferative and matrix-producing repair [15]. Accordingly, effects of senescent-cell clearance are stage- and model-dependent. In Ldlr-/- mice, p16-directed genetic clearance reduced plaque burden and increased cap thickness, while نافيتوكلاكس reduced aortic plaque burden [57]. In Apoe-/- mice, p16-driven clearance did not reduce plaque burden, cap thickness, or اللب النخري area and increased apoptotic cells and التهاب, while navitoclax reduced lesion size without increasing cap thickness [58]. In Apoe-/- mice with advanced lesions and persistent hyperlipidemia, navitoclax reduced smooth-muscle-derived cells within the غِلاف ليفي, decreased cap thickness, and increased mortality [59]. Thus, pharmacological senolysis in advanced experimental atherosclerosis can deplete reparative cap cells and compromise plaque stability, materially qualifying therapeutic inference.

2.4 Mitochondrial dysfunction, mitophagy, and vascular inflammaging

In murine vascular-aging models, aged arterial tissue exhibits declining mtDNA copy number and reduced expression of the copy-number regulators TFAM, PGC-1alpha, and the mtDNA helicase Twinkle [17]. These changes track with reduced mitochondrial respiration, decreased carotid compliance and distensibility, and rising aortic pulse wave velocity [17]. Transgenic Twinkle overexpression increases mtDNA copy number, improves arterial respiration, and delays vascular aging in that model, whereas polymerase-gamma-mutant mice with degraded mtDNA integrity age faster [17]. In ApoE-/- mice, related mitochondrial rescue reduces necrotic-core area and increases relative fibrous-cap thickness [18]. This evidence base is predominantly murine; equivalent longitudinal human vascular Twinkle data do not exist.

Damaged mitochondria are cleared through mitophagy. In the canonical PINK1/Parkin pathway, depolarization stabilizes PINK1 on the outer membrane and recruits Parkin, which ubiquitylates outer-membrane proteins including MFN1, MFN2, and VDAC1 and targets the organelle for autophagic-lysosomal degradation [19]. Parkin-independent pathways also exist.

The relationship between aging and mitophagic flux in the vessel wall is more complicated than a simple decline. In aged murine الوريد الأبهر, Parkin protein and mitophagy markers are increased alongside elevated IL-6 and impaired respiration, consistent with compensatory or stalled mitophagy responding to a rising burden of damaged organelles rather than simple pathway loss [19]. Increased pathway markers do not establish increased successful flux. Global autophagic capacity declines with age in many tissues, and available data are consistent with clearance becoming insufficient relative to damaged-organelle burden in the aged artery [50]. Persistent damaged mitochondria can generate mitochondrial reactive oxygen species and release mitochondrial damage-associated molecular patterns, including unmethylated CpG mtDNA, into the cytosol [19].

Cytosolic mitochondrial damage-associated molecular patterns engage NLRP3 inflammasome and TLR9/MyD88 signaling. In the murine model in which this pathway was demonstrated, this signaling contributes to a feed-forward IL-6-associated inflammatory loop linking mitochondrial dysfunction to increased atherogenesis [19]. An equivalent longitudinal causal sequence has not been demonstrated in humans.

2.5 Clonal hematopoiesis of indeterminate potential (CHIP)

Clonal hematopoiesis of indeterminate potential (CHIP) denotes age-related acquisition of somatic mutations in leukemia-associated driver genes within hematopoietic stem and progenitor cells, traditionally operationalized by detection of a driver mutation at variant allele fraction (VAF) >=2% in the absence of persistent unexplained cytopenia and without a diagnosable hematologic neoplasm [20]. When persistent otherwise unexplained cytopenia coexists with clonality, current classifications designate clonal cytopenia of undetermined significance (CCUS), which carries a different malignant-progression risk [21]. The cardiovascular literature summarized here concerns CHIP, not CCUS. Prevalence rises from <1% below age 40 to approximately 10% among adults older than 70 in early sequencing cohorts, with higher estimates when deep sequencing detects clones below the 2% threshold [20]. The 2% VAF cutoff is an assay and reporting convention, not a biological boundary.

Dominant drivers include DNMT3A, TET2, and ASXL1, with JAK2 V617F less common but functionally distinctive [20,22]. In Tet2-deficient murine البالعات الكبيرة, loss of function augments IL-1beta and IL-6 signaling in association with NLRP3 inflammasome activation [23].

Effect sizes require precision. CHIP carriers had approximately 1.9- to 2.0-fold the risk of incident coronary heart disease in nested case-control analyses of the BioImage and Malmö Diet and Cancer cohorts and approximately 4-fold higher odds of early-onset myocardial infarction in ATVB and PROMIS [22]. The often-quoted ~12-fold figure applies specifically to JAK2 V617F carriers in the original cohort estimate, whereas DNMT3A, TET2, and ASXL1 were associated with roughly 1.7- to 2.0-fold risk [22]. It is gene-specific, not clone-size-specific, and should not be restated as “VAF above 10% confers a 12-fold increase.” Larger clones (VAF >=10%) are separately associated with greater cardiovascular and all-cause risk in observational cohorts, and CHIP carriers show higher coronary artery calcium scores than noncarriers [20,22].

Biological causality is supported in mice: in hyperlipidemic Ldlr-/- animals, reconstitution with Tet2-deficient bone marrow increases lesion size and necrotic-core burden [23]. These experiments establish that the mechanism can operate, not the magnitude or universality of a causal effect in humans.

In an exploratory genomic substudy of CANTOS, 338 sequenced participants (8.6%) carried clonal hematopoiesis; TET2 carriers appeared to derive greater MACE reduction from canakinumab than noncarriers [24]. This is hypothesis-generating subgroup evidence, not a demonstrated treatment-effect modifier.

Counter-evidence remains important. In a pooled analysis of 63,700 participants from five randomized cardiovascular outcome trials, CHIP carriage was not significantly associated with major cardiovascular events (adjusted HR 1.07, 95% CI 0.99-1.16) [25]. In the PESA cohort, baseline clonal hematopoiesis was associated with subsequent de novo femoral atherosclerosis over approximately six years, whereas atherosclerotic burden did not measurably accelerate mutant-clone expansion over the same period [26]. These findings support a predominant direction from clonal hematopoiesis toward atherosclerosis while not excluding reciprocal effects in other settings. CHIP remains biologically compelling and experimentally supported; its independent prognostic value in intensively treated secondary-prevention populations is less certain than community-cohort literature implies.

2.6 Endothelial progenitor cells and proteotoxic stress

Circulating cell populations historically classified as endothelial progenitor cells show age-associated reductions in number or function in some assays, but findings depend on assay and surface-marker phenotype [1]. “Endothelial progenitor cell” does not denote a single defined lineage. Many populations given that label are hematopoietic or angiogenic cells rather than bona fide endothelial progenitors, and endothelial colony-forming cells are not equivalent to CD34/KDR flow-cytometric or culture-based assays. The association between reduced progenitor measures and vascular dysfunction in older adults is reasonably consistent; the inference that progenitor failure causes impaired repair is not established.

Experimental and observational evidence also suggests that aging can compromise vascular proteostasis: declining ubiquitin-proteasome activity and impaired chaperone function may permit accumulation of misfolded and aggregated proteins in endothelial cells and VSMCs, promoting proteotoxic stress, unfolded-protein responses, and ER-stress-mediated apoptosis [1]. Individual steps are better established in nonvascular tissue than in the human arterial wall, so this sequence is presented as a mechanistic model rather than a demonstrated human pathway.

Table 3. Mechanisms of vascular aging, mediators, and atherosclerosis-related phenotype or effect.

Biological mechanism	Primary molecular mediators	Direct vascular consequence	Atherosclerosis-related phenotype or effect	Evidence tier (as cited)
Matrix degradation and AGE cross-linking [8,9]	Collagen cross-linking, AGE-RAGE, elastase, MMPs	Stiffening, rising PWV and systolic BP, reduced compliance	Lipoprotein retention and monocyte entry in low-ESS regions (<10-12 dyn/cm2 is a commonly used research definition; method-dependent)	Human observational + mechanistic
Local Ang-II signaling [10,11]	Locally regulated intramural Ang-II; ACE, chymase, AT1	VSMC hypertrophy, synthetic switching, MMP-2 activation	Age-associated arterial remodeling; carotid IMT increases longitudinally by ~0.01 mm/yr in population data [12]	Animal + human tissue
Cellular senescence and SASP [1,14-16]	p16INK4a, p21CIP1, SA-beta-gal, MMP-2/9, IL-6, IL-1beta	Replicative arrest, ECM degradation, paracrine spread	Co-localization with calcified and advanced lesion regions in human tissue; causal effects primarily in animal models, with cap effects model- and stage-dependent	Human histology [14] + animal [15,45]
Mitochondrial dysfunction and dysregulated or insufficient mitophagic quality control [17-19,50]	Reduced mtDNA copy number, TFAM, PGC-1alpha, Twinkle; PINK1/Parkin dysregulation; mtDAMPs	Elevated mROS, NLRP3 and TLR9/MyD88 activation	Feed-forward IL-6/mROS signaling in animal models; reduced compliance; necrotic core [18]	Animal primary; human inferred
CHIP [20,22-24]	TET2, DNMT3A, ASXL1, JAK2 V617F (VAF >=2%)	Driver-dependent myeloid skewing, monocyte hyper-reactivity, IL-1beta/IL-6 excess	~2x CHD; ~4x early-onset MI; JAK2 V617F ~12x CHD risk in the original cohort estimate; higher CAC; lesion growth in mice	Human علم الوبائيات + causal animal model + longitudinal human imaging; prognostic magnitude heterogeneous in treated trial populations [25,26]
Progenitor decline and proteotoxicity [1]	Heterogeneous progenitor populations, telomere attrition, UPS dysfunction, UPR	Association with impaired endothelial repair; intracellular proteotoxicity	Barrier disruption and apoptosis (model, not demonstrated pathway)	Human observational, methodologically heterogeneous

3. Therapeutic mitigation strategies

3.1 Nutritional therapeutics: the CORDIOPREV evidence

The randomized, single-blind CORDIOPREV trial enrolled 1,002 patients with established coronary heart disease and followed them for a median of 7 years, comparing a Mediterranean dietary pattern enriched in extra-virgin زيت زيتون (EVOO; 35% total fat, 22% monounsaturated fatty acids, <50% carbohydrate) with a low-fat diet (28% fat, 12% monounsaturated fatty acids, >55% -omplex carbohydrate) [27,28]. The cohort had a mean age of 59.5 years (SD 8.7) and was 82.5% male [28], so extension to octogenarians is extrapolation. It. Is important to note that the low fat arm herein is substantially higher than other diets and is only slightly lower than the EVOO component.

Among 939 participants with baseline carotid imaging, the حمية البحر الأبيض المتوسط decreased common carotid IMT at 5 years (-0.027 +/- 0.008 mm; P<0.001) and maintained the reduction at 7 years (-0.031 +/- 0.008 mm; P<0.001) relative to baseline; the low-fat diet produced no change [27]. Maximum carotid plaque height was reduced in the Mediterranean arm relative to the low-fat arm across follow-up, whereas plaque number did not differ [27]. These are group-level structural changes. Common carotid IMT progression is not a validated surrogate for cardiovascular-event reduction; in the PROG-IMT individual-participant تحليل تلوي, IMT progression did not independently predict cardiovascular events [54].

الـ كورديوبريف primary endpoint was a prespecified composite of myocardial infarction, revascularization, ischemic stroke, peripheral artery disease, and cardiovascular death [28], not the same MACE definition used in many pharmacological trials. Events occurred in 198 participants: 87 in the Mediterranean arm and 111 in the low-fat arm (28.1 versus 37.7 per 1,000 person-years; log-rank P=0.039) [28]. Multivariable-adjusted hazard ratios across model specifications ranged from 0.719 (95% CI 0.541-0.957) to 0.753 (95% CI 0.568-0.998), corresponding to approximately 25-28% lower estimated hazard [28]. The upper confidence bound in the least favorable model approaches unity, and the trial was single-center and unblinded to participants.

Long-term consumption of the EVOO-rich Mediterranean diet was also associated with slower decline in estimated الترشيح الكبيبي rate, with a larger difference among participants with type 2 diabetes or mild renal impairment [29]. This is a secondary renal-function outcome, not a demonstrated renoprotective clinical effect. MEDLIFE analyses are observational within the randomized cohort and are discussed in Section 3.4.

CORDIOPREV tested a whole dietary pattern and cannot attribute effects to isolated EVOO components. Biomarker substudies demonstrate modulation of circulating AGEs in association with IMT change but do not establish a component-specific mechanism [31]. Assertions that individual polyphenols suppress SASP secretion require separate primary experimental evidence and are not supported by the clinical trial itself.

3.2 Pharmacological interventions

The March 2026 ACC/AHA/Multisociety Dyslipidemia Guideline replaced the 2018 blood cholesterol guideline. It adopts the منع المعادلات to guide primary-prevention lipid-lowering decisions, restores LDL-C and non-HDL-C treatment goals with lower targets for higher-risk groups, expands the role of coronary artery calcium scoring for risk إعادة تصنيف, recommends measuring بروتين دهني (أ) at least once, and states that after age 75 years LDL-C-lowering pharmacotherapy can be considered in conjunction with lifestyle interventions to reduce ASCVD risk [32]. Thus, the post-75 population does not lack contemporary guidance; what remains limited is dedicated randomized evidence specifically addressing statin initiation for primary prevention after age 75.

In the Cholesterol Treatment Trialists’ Collaboration meta-analysis of 28 trials, statin therapy produced a significant proportional reduction in major vascular events per 1.0 mmol/L LDL-C reduction in participants older than 75 with pre-existing vascular disease, with no evidence that proportional benefit is abolished by age [7]. Higher baseline event rates can translate preserved relative effects into larger absolute benefits, although realized benefit depends on competing risk, التزام, and treatment horizon [7,34].

Dedicated randomized evidence for primary prevention after age 75 remains limited. STAREE (NCT02099123) randomized 9,971 community-dwelling Australians aged >=70 years (mean 74.7; 40% >=75; 52% women; mean baseline LDL-C 126 mg/dL) without clinical cardiovascular disease, diabetes, or dementia to atorvastatin 40 mg or دواء موهم, with co-primary endpoints of disability-free survival and major cardiovascular events [35]. Recruitment ran from July 2015 through March 2023. As of August 13, 2026, no peer-reviewed primary-outcome report had been published.

PREVENTABLE (NCT04262206) is randomizing 20,000 US adults aged >=75 years without clinically evident cardiovascular disease, disability, or dementia to atorvastatin 40 mg or placebo across approximately 100 sites. Its primary outcome is survival free of new dementia or persisting disability; cardiovascular events are secondary outcomes [36]. No peer-reviewed primary results had been published as of August 13, 2026. The endpoint asymmetry matters: PREVENTABLE’s primary endpoint is a geriatric functional composite rather than conventional MACE. The US Preventive Services Task Force continues to judge evidence insufficient to assess benefits and harms of statin initiation for primary prevention in adults aged 76 years and older [37].

A separate 2026 French pragmatic, open-label non-inferiority trial addressed discontinuation rather than initiation. Among 1,160 adults aged >=75 years who had taken a statin for at least one year for primary prevention and had no ASCVD history, three-year الوفيات لجميع الأسباب was 7.2% after discontinuation versus 7.9% with continuation, meeting the prespecified non-inferiority criterion [55]. This finding does not establish cardiovascular-event equivalence, does not answer the initiation question, and should be interpreted in light of open-label design and lower-than-anticipated mortality.

Age-related pharmacokinetic changes are heterogeneous. Reduced total body water and lean mass, lower functional hepatic volume, and declining renal function can alter distribution and clearance [33,38]. Renal clearance contributes more to several hydrophilic statins, whereas atorvastatin and simvastatin rely predominantly on hepatic metabolism and transporter-mediated handling [38]. Older adults report statin-associated muscle symptoms more frequently in observational settings, but this does not establish greater statin-attributable muscle toxicity because multimorbidity, interacting medications, background musculoskeletal symptoms, and ascertainment differ [38]. The SAMS-CI can support structured assessment [39]. In the SAMSON n-of-1 crossover trial, most of the excess symptom burden participants attributed to statins was also observed during placebo exposure [40]. Management options include dose reduction, alternate-day dosing, agent switching, and non-statin add-on therapy [38]. In JUPITER, rosuvastatin was associated with a 28% relative increase in incident diabetes among participants with at least one major diabetes عامل خطر, with no significant excess among those without such risk factors; vascular events and deaths prevented exceeded incident diabetes cases in that population [41].

CANTOS demonstrated that quarterly canakinumab reduced recurrent cardiovascular events in post-myocardial-infarction patients with hsCRP >=2 mg/L independently of lipid lowering [42]. A secondary analysis associated larger on-treatment hsCRP reductions with greater event reduction, but because it stratified by post-randomization response it does not establish a predictive biomarker strategy [60]. Canakinumab increased fatal infection and is not approved for a cardiovascular indication.

LoDoCo2 showed that کولشیسين 0.5 mg once daily reduced its primary نقطة نهاية مركبة in chronic coronary disease (HR 0.69, 95% CI 0.57-0.83) [43], with a numerical excess of non-cardiovascular death that remains incompletely explained. By contrast, CLEAR SYNERGY (OASIS 9) found no reduction in cardiovascular death, recurrent myocardial infarction, stroke, or ischemia-driven revascularization after acute MI treated with PCI: 9.1% versus 9.3% with placebo (HR 0.99, 95% CI 0.85-1.16; P=0.93) [56]. The عدم توافق does not support a uniform benefit narrative. Differences in disease phase, dose regimen, background therapy, event rates, and trial conduct have been proposed but not established as explanations.

Colchicine safety is particularly relevant in geriatric polypharmacy. Renal or hepatic impairment and concomitant strong CYP3A4 or P-glycoprotein inhibitors materially affect toxicity and dosing. Interacting drugs include clarithromycin, several azole antifungals, verapamil, diltiazem, and cyclosporine; current product labeling and the 2023 chronic coronary disease guideline should be consulted [44]. The guideline assigns low-dose colchicine a Class 2b recommendation in chronic coronary disease [44]. LoDoCo2 did not select patients by hsCRP or another inflammatory biomarker; it should therefore not be described as biomarker-directed.

3.3 Geroprotective strategies: preclinical status

All approaches in this section are preclinical or early-phase with respect to atherosclerotic endpoints. None is clinically indicated for atherosclerosis.

Dasatinib plus quercetin and the BCL-2-family inhibitor navitoclax can preferentially induce apoptosis in certain senescent-cell populations. “Senolytic” is not a mechanism with a predictable class effect: these agents differ substantially in molecular target and in the senescent-cell populations they deplete. In aged and atherosclerotic mice, chronic senolytic treatment can alleviate vasomotor dysfunction and reduce aortic calcification and intrinsic wall stiffness [45]. Effects on plaque stability, however, are stage- and model-dependent. In advanced lesions, navitoclax has reduced smooth-muscle-derived fibrous-cap cells, decreased cap thickness, and increased mortality, conflicting with earlier reports of cap thickening [57-59]. Human experience is confined to small open-label and early-phase studies in idiopathic pulmonary fibrosis [46] and diabetic مرض الكلى [47], with physical-function or senescent-cell-burden endpoints. No human trial has tested a senolytic against an atherosclerotic clinical endpoint.

Oral spermidine improved aortic pulse wave velocity and nitric-oxide-mediated endothelial dilation and reduced aortic AGEs, collagen I, nitrotyrosine, and superoxide in aged mice [48]. In aged hyperlipidemic mice, spermidine attenuated mitochondrial dysfunction and atherogenesis [19]. In ApoE-/- mice, spermidine reduced necrotic-core formation and lipid accumulation without changing plaque size or cellular composition, and the effect required intact smooth-muscle autophagy [49].

Metformin has been proposed as a geroprotective agent, and the Targeting Aging with Metformin (TAME) concept remains a framework for testing whether intervention on aging biology can delay multimorbidity [51]. TAME remains a design proposal rather than a completed study, and no TAME efficacy data had been published as of August 13, 2026. No clinical evidence demonstrates that metformin improves atherosclerotic outcomes through a distinct geroprotective mechanism. mTOR inhibitors attenuate mitochondrial ROS and modulate SASP in model systems, but vascular-specific evidence is thinner and rapalogs carry immunosuppressive and dyslipidemic effects that are non-trivial in older adults.

3.4 Hemodynamic and lifestyle mitigation

Psychosocial stress is associated with adverse cardiovascular outcomes through interacting behavioral, autonomic, neuroendocrine, inflammatory, and hemodynamic pathways [62]. The contribution of individual vascular-aging mechanisms in humans remains uncertain.

Blood-pressure control has direct randomized support in older adults. In HYVET, خافض ضغط الدم treatment in patients aged 80 years and older reduced stroke, heart failure, and all-cause mortality [52]. In the SPRINT subgroup aged >=75 years, intensive systolic targeting reduced major cardiovascular events and all-cause mortality, with broadly consistent findings across frailty strata [53]. Intensive treatment requires monitoring for hypotension, syncope, electrolyte abnormalities, and acute kidney injury; SPRINT did not demonstrate an excess of injurious falls [53]. Renin-angiotensin-aldosterone system inhibition additionally reduces Ang-II signaling and can favorably affect vascular remodeling and central hemodynamics [8,10], but HYVET and SPRINT do not establish that these vascular-aging mechanisms mediate clinical benefit.

In a five-year prospective analysis of 851 CORDIOPREV participants, high MEDLIFE adherence (>13 points) was associated with lower adjusted odds of developing متلازمة الأيض (OR 0.37, 95% CI 0.19-0.75) and higher odds of reversing pre-existing metabolic syndrome (OR 2.08, 95% CI 1.11-3.91) versus the low-adherence group (<12 points) [30]. These are observational associations within a randomized cohort: participants were not randomized to the lifestyle index, adherence was self-reported, and residual confounding is likely. Regular aerobic activity is associated with better-preserved الوظيفة البطانية in older adults [1]. Proposed mechanisms — including shear-related eNOS signaling, lower circulating inflammatory cytokines, and improved mitochondrial quality control — are supported chiefly by physiological and animal studies rather than randomized vascular-outcome data.

Table 4. Mitigation strategies by domain, mechanism, outcome, and evidence tier. Evidence-tier labels describe the sources cited in each row.

Domain	Intervention	Targeted mechanism	Principal outcome	Evidence tier (as cited)
Nutritional [27-29,31]	EVOO-rich Mediterranean dietary pattern	Whole-pattern anti-inflammatory and endothelial effects; AGE modulation	CORDIOPREV adjusted HR 0.719-0.753 (~25-28% lower estimated hazard) for the prespecified cardiovascular composite; IMT-CC -0.031 mm at 7 yr (group-level structural outcome, not a validated event surrogate); slower eGFR decline as a secondary outcome	RCT (mean age 59.5 yr; extrapolation to older adults)
Lipid management [7,32,35-38,55]	Moderate/high-intensity statin and other LDL-lowering therapy as appropriate	إنزيم HMG-CoA المختزل inhibition, apoB lowering, استقرار اللويحة	Established secondary-prevention benefit in older adults; 2026 guideline permits consideration of LDL-C-lowering pharmacotherapy after 75; dedicated initiation trials pending; discontinuation trial did not establish cardiovascular equivalence or answer initiation	RCT/meta-analysis + current guideline
Anti-inflammatory [42-44,56]	Colchicine 0.5 mg daily; canakinumab (not approved for CV use)	Microtubule-dependent inflammatory signaling; IL-1beta/NLRP3-related pathways	LoDoCo2: HR 0.69 in chronic coronary disease; CLEAR SYNERGY: 9.1% vs 9.3% after MI; neither colchicine trial biomarker-selected	RCT (discordant) + guideline (Class 2b)
Geroprotective [15,19,45-51,57-59]	Senolytics, spermidine, metformin, rapalogs	Senescent-cell clearance, autophagy/mitophagy modulation, mTOR inhibition	Preclinical effects include reduced necrotic core, calcification, or vasomotor dysfunction; cap effects are stage- and model-dependent and conflicting; no demonstrated human atherosclerotic outcome benefit	Preclinical; early-phase human in other indications
Hemodynamic [8,10,52,53]	Antihypertensive therapy; ACE inhibition/ARB	BP lowering; blockade of intramural Ang-II signaling	HYVET and SPRINT >=75 subgroup: reduced clinical events and mortality	RCT + mechanistic
Lifestyle [1,30]	MEDLIFE adherence, تمرين هوائي	Favorable endothelial shear-related signaling, eNOS up-regulation, reduced inflammaging	MEDLIFE observational associations: incident metabolic syndrome OR 0.37; عكس OR 2.08	Observational within randomized cohort

4. Limitations

First, this is a narrative review. Sources were selected for representativeness rather than by a prespecified search and screening protocol, and selection bias toward well-cited mechanistic literature cannot be excluded.

Second, the mechanistic architecture of vascular aging rests substantially on rodent and nonhuman-primate work. For several pathways, human evidence remains predominantly cross-sectional tissue, biomarker, or associative data rather than direct longitudinal intervention.

Third, the randomized dietary evidence anchoring Section 3.1 comes from a single-center trial with a predominantly male, middle-aged cohort, and its generalization to geriatric populations is inferential.

Fourth, the CHIP literature remains in flux. Causal animal data are strong, community- and population-based cohort associations are robust, and treated-trial-population data are comparatively null. Endpoint heterogeneity, clone composition, background therapy, القوة الإحصائية, and selection into randomized trials all differ across these datasets; attributing discordance to any single explanation would be premature.

Fifth, carotid IMT is used as a structural readout, but IMT progression has not been shown to predict events independently in individual-participant meta-analysis [54]; structural regression should not be equated with event reduction.

5. Conclusions

The incidence of clinical atherosclerotic events rises steeply with advancing age [4]. Age-related vascular mechanisms may contribute to earlier clinical disease and to greater atherosclerotic burden than would be predicted from measured conventional risk factors alone — two of the operational phenotypes defined in Section 1.0. Whether the longitudinal rate of human plaque accumulation itself accelerates with chronological age remains undemonstrated. The rise in event incidence among older adults is best understood as age-associated vascular processes superimposed on cumulative apoB exposure rather than replacement of lipoprotein-mediated atherogenesis [2,6].

In the aging vessel wall, matrix degradation, AGE cross-linking, altered intramural angiotensin II signaling, mitochondrial dysfunction, impaired mitochondrial quality control, and cellular senescence constitute candidate or experimentally supported pathways capable of promoting atherogenesis or contributing to features associated with plaque vulnerability [16]. Evidence strength is not uniform: human tissue and histologic data support matrix, angiotensin-II, and senescence pathways, whereas mitochondrial and mitophagy evidence is primarily murine and lacks an equivalent longitudinal human vascular counterpart.

Age-related somatic mutation in hematopoietic stem cells, manifesting as CHIP, can promote driver-dependent inflammatory signaling and is causally sufficient to accelerate atherogenesis in experimental models. Human imaging supports a predominant direction from clonal hematopoiesis toward atherosclerosis, without excluding reciprocal contribution, while CHIP’s independent prognostic weight in intensively treated human populations remains contested [22-26].

Mitigation is multimodal. CORDIOPREV supports a Mediterranean dietary pattern in secondary prevention but was not a geriatric trial [27,28]. Statin therapy has established secondary-prevention benefit in older adults, and the 2026 multisociety guideline states that LDL-C-lowering pharmacotherapy can be considered after age 75 alongside lifestyle intervention; STAREE and PREVENTABLE are intended to inform remaining primary-prevention uncertainty [32,35,36]. Low-dose colchicine reduced events in LoDoCo2 in chronic coronary disease but was neutral in CLEAR SYNERGY after myocardial infarction [43,56]. Blood-pressure lowering has direct randomized support in adults aged 75 years and older [52,53]. Senotherapeutic and mitophagy-directed strategies remain investigational, with no demonstrated clinical atherosclerotic outcome benefit in humans [15,19,45-51,57-59].

Current management therefore remains centered on lowering exposure to apoB-containing lipoproteins, blood-pressure control, smoking avoidance and cessation, management of diabetes and related metabolic risk where applicable, dietary quality, and physical activity. Low-dose colchicine may be considered in appropriately selected patients with chronic coronary disease according to contemporary guidelines and patient-specific contraindications.

Declarations

Funding. This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest. The author declares no competing interests.

Data availability. Not applicable. This article is a narrative review and reports no original participant-level data.

Ethics approval. Not applicable. This narrative review involved no original enrollment of human participants or animals and no generation of identifiable participant-level data.

Use of generative AI. The author used a large language model to assist with drafting, editing, and reference formatting. The author reviewed and verified all content, is responsible for all scientific claims and citations, and takes full responsibility for the integrity and accuracy of the submitted work.

المراجع

1. Head T, Daunert S, Goldschmidt-Clermont PJ. The aging risk and atherosclerosis: a fresh look at arterial homeostasis. Front Genet. 2017;8:216.
2. Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68.
3. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-e743.
4. Palaniappan LP, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;153(9):e275-e906.
5. Hazzard WR, Ettinger WH Jr. Aging and atherosclerosis: changing considerations in cardiovascular disease prevention as the barrier to immortality is approached in old age. Am J Geriatr Cardiol. 1995;4(4):16-36.
6. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
7. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-415.
8. Fleg JL, Strait J. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease. Heart Fail Rev. 2012;17(4-5):545-554.
9. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379-2393.
10. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am. 2009;93(3):583-604.
11. Wang M, Takagi G, Asai K, et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension. 2003;41(6):1308-1316.
12. Rosvall M, Persson M, Östling G, et al. Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: the Malmö Diet and Cancer Study. Atherosclerosis. 2015;239(2):615-621.
13. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima-media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 1999;30(4):841-850.
14. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541-1544.
15. Molnár ÁÁ, Pásztor DT, Tarcza Z, Merkely B. Cells in atherosclerosis: focus on cellular senescence from basic science to clinical practice. Int J Mol Sci. 2023;24(24):17129.
16. Chakrabarti A, Goldstein DR, Sutton NR. Age-associated arterial calcification: the current pursuit of aggravating and mitigating factors. Curr Opin Lipidol. 2020;31(5):265-272.
17. Foote K, Reinhold J, Yu EPK, Figg NL, Finigan A, Murphy MP, et al. Restoring mitochondrial DNA copy number preserves mitochondrial function and delays vascular aging in mice. Aging Cell. 2018;17(4):e12773.
18. Yu EPK, Reinhold J, Yu H, et al. Mitochondrial respiration is reduced in atherosclerosis, promoting necrotic core formation and reducing relative fibrous cap thickness. Arterioscler Thromb Vasc Biol. 2017;37(12):2322-2332.
19. Tyrrell DJ, Blin MG, Song J, et al. Age-associated mitochondrial dysfunction accelerates atherogenesis. Circ Res. 2020;126(3):298-314.
20. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
21. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
22. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121.
23. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-847.
24. Svensson EC, Madar A, Campbell CD, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 2022;7(5):521-528.
25. Marston NA, Pirruccello JP, Melloni GEM, et al. Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials. Nat Med. 2024;30(9):2641-2647.
26. Díez-Díez M, Ramos-Neble BL, de la Barrera J, et al. Unidirectional association of clonal hematopoiesis with atherosclerosis development. Nat Med. 2024;30(10):2857-2866.
27. Jimenez-Torres J, Alcala-Diaz JF, Torres-Peña JD, et al. Mediterranean diet reduces atherosclerosis progression in coronary heart disease: an analysis of the CORDIOPREV randomized controlled trial. Stroke. 2021;52(11):3440-3449.
28. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al.; CORDIOPREV Investigators. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876-1885.
29. Podadera-Herreros A, Alcala-Diaz JF, Gutierrez-Mariscal FM, et al. Long-term consumption of a Mediterranean diet or a low-fat diet on kidney function in coronary heart disease patients: the CORDIOPREV randomized controlled trial. Clin Nutr. 2022;41(2):552-559.
30. Romero-Cabrera JL, Garcia-Rios A, Sotos-Prieto M, et al. Adherence to a Mediterranean lifestyle improves metabolic status in coronary heart disease patients: a prospective analysis from the CORDIOPREV study. J Intern Med. 2023;293(5):574-588.
31. Gutierrez-Mariscal FM, Lopez-Moreno A, Torres-Peña JD, et al. Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial. Cardiovasc Diabetol. 2024;23(1):361.
32. Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757.
33. Nguyen TN, Woodward M, Butt JH, McMurray JJV, Lip GYH, Kaski JC. Optimizing cardiovascular pharmacotherapy in older adults with frailty. Nat Rev Cardiol. 2026;23:433-443.
34. Baratta F, Moscucci F, Lospinuso I, Cocomello N, Bruno G, Cangemi R, et al. Lipid-lowering therapy and cardiovascular prevention in elderly. Drugs. 2025;85(6):801-812.
35. Zoungas S, Curtis A, Tonkin A, et al. Baseline characteristics of participants in STAREE: a randomized trial for primary prevention of cardiovascular disease events and prolongation of disability-free survival in older people. J Am Heart Assoc. 2024;13(23):e036357.
36. Joseph J, Pajewski NM, Dolor RJ, et al.; PREVENTABLE Trial Research Group. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-1713.
37. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(8):746-753.
38. Stone J, Kumar M, Orkaby AR. The role of statin therapy in older adults: best practices and unmet challenges. Expert Rev Cardiovasc Ther. 2024;22(7):301-311.
39. Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179-186.
40. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182-2184.
41. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.
42. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
43. Nidorf SM, Fiolet ATL, Mosterd A, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847.
44. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Circulation. 2023;148(9):e9-e119.
45. Roos CM, Zhang B, Palmer AK, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell. 2016;15(5):973-977.
46. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563.
47. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
48. LaRocca TJ, Gioscia-Ryan RA, Hearon CM, Seals DR. The autophagy enhancer spermidine reverses arterial aging. Mech Ageing Dev. 2013;134(7-8):314-320.
49. Michiels CF, Kurdi A, Timmermans JP, De Meyer GRY, Martinet W. Spermidine reduces lipid accumulation and necrotic core formation in atherosclerotic plaques via induction of autophagy. Atherosclerosis. 2016;251:319-327.
50. Zeng Y, Buonfiglio F, Li J, Pfeiffer N, Gericke A. Mechanisms underlying vascular inflammaging: current insights and potential treatment approaches. Aging Dis. 2025;16(4):1889-1917.
51. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.
52. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
53. Williamson JD, Supiano MA, Applegate WB, et al.; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >=75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-2682.
54. Lorenz MW, Polak JF, Kavousi M, et al.; PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet. 2012;379(9831):2053-2062.
55. Bonnet F, Poulizac P, Rousselot N, Couffinhal T, Galli G, Berdaï D, et al.; SAGA/SITE Study Group. Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial. Lancet Healthy Longev. 2026;7:100884.
56. Jolly SS, d’Entremont MA, Lee SF, et al.; CLEAR Investigators. Colchicine in acute myocardial infarction. N Engl J Med. 2025;392(7):633-642.
57. Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016;354(6311):472-477.
58. Garrido AM, Kaistha A, Uryga AK, et al. Efficacy and limitations of senolysis in atherosclerosis. Cardiovasc Res. 2022;118(7):1713-1727.
59. Karnewar S, Karnewar V, Shankman LS, Owens GK. Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality. JCI Insight. 2024;9:e173863.
60. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328.
61. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105(7):816-822.
62. Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783.